DONOR CARD
Development of a Nitric Oxide Releasing Stent for Treatment of Coronary Artery Disease
| Coordinatore | BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST
Organization address
address: "Royal Sussex County Hospital, Eastern Road" contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 986˙284 € |
| EC contributo | 986˙284 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2009-IAPP |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-12-01 - 2014-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST
Organization address
address: "Royal Sussex County Hospital, Eastern Road" contact info |
UK (BRIGHTON) | coordinator | 284˙360.00 |
| 2 |
Hexacath SAS
Organization address
address: Passage St Antoine 4 contact info |
FR (Rueil-Malmaison) | participant | 428˙710.00 |
| 3 |
UNIVERSITY OF BRIGHTON
Organization address
address: "Lewes Road, Mithras House" contact info |
UK (BRIGHTON) | participant | 273˙214.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Coronary artery disease is one of the leading causes of death worldwide. Significant advances in treating coronary artery disease have been made over the last decade with the introduction of percutaneous coronary intervention (PCI). PCI involves the placement of stents within narrowed arteries relieving the symptoms of angina and in some cases increasing life expectancy. The two major problems with currently available stent designs are restenosis and late thrombosis. The former is more common in uncoated stents and was addressed with the introduction of drug releasing stents. However, concerns have been raised about the increased incidence of stent thrombosis with these drug releasing stents. An innovative design of stent utilising titanium oxynitride (Titan 2) was the first of the bioactive stents which compared favourably in efficacy to the drug coated stents but with less re-narrowing than with the uncoated stents. The Titan 2 uses the fundamental biocompatibility of titanium to reduce inflammation and promote healing after stenting. Nitrous oxide (NO) is an important regulator of endothelial cell function. We will design a bioactive titanium oxynitride coated stent which will release NO after stent implantation. It is proposed that this will have beneficial effects to endothelial function after stenting and possibly reduce the incidence of re-narrowing and stent thrombosis. The new metal stent will be tested in vitro using primary human monocytes and platelets and using a human derived endothelial cell line. We aim to achieve excellent biomaterial properties as applied to coronary artery stenting, a highly biocompatible surface and to demonstrate release of NO after stent deployment. To achieve this we will combine the knowledge of our industrial, medical and scientific partners to develop a new coronary stent which will be of significant benefit to patients with coronary artery disease both in the European Union and worldwide.'